Recursion Pharmaceuticals, Inc. (RXRX)
$
4.83
-0.02 (-0.41%)
Key metrics
Financial statements
Free cash flow per share
-0.9374
Market cap
2.1 Billion
Price to sales ratio
32.0281
Debt to equity
0.0958
Current ratio
3.5797
Income quality
0.5901
Average inventory
0
ROE
-0.7607
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on decoding biology through the integration of technological innovations in various fields such as biology, chemistry, automation, data science, and engineering, ultimately aiming to industrialize drug discovery. The company reported an income before tax of -$464,788,000.00 showcasing its pre-tax profitability. Its gross profit stands at $13,601,000.00 highlighting the company's profitability from core operations. However, the company incurred an income tax expense of -$1,127,000.00 indicating its tax obligations. Additionally, Recursion Pharmaceuticals reported selling, general, and administrative expenses of $178,184,000.00 which indicate operational overhead costs. The company also incurred an interest expense of $1,572,000.00 reflecting its debt servicing obligations. In terms of drug development, Recursion is advancing several candidates including REC-994, currently in Phase IIa clinical trials for treating cerebral cavernous malformation; REC-2282 for neurofibromatosis type 2; REC-4881 for familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trials for GM2 gangliosidosis. Its pipeline further includes various preclinical stage products targeting different conditions. The company has collaborative agreements with entities such as Bayer AG and the University of Utah Research Foundation, contributing to its research and development initiatives. Recursion Pharmaceuticals was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Investors may find the stock is affordable at $4.83 making it suitable for budget-conscious individuals. The stock enjoys a high average trading volume of 24,145,738.00 indicating strong liquidity within the market. With a mid-range market capitalization of $2,063,921,790.00 the company is viewed as a steady performer. It holds a significant position in the Biotechnology industry, contributing meaningfully to the overall market landscape. Furthermore, Recursion Pharmaceuticals belongs to the Healthcare sector, driving innovation and growth within the field. Overall, the company presents an intriguing opportunity for those looking to invest in a biotechnology firm actively engaged in addressing diverse medical needs through its innovative drug development efforts.
Is Recursion Pharmaceuticals, Inc. (RXRX) a good investment?
Investing in Recursion Pharmaceuticals, Inc. (RXRX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Recursion Pharmaceuticals, Inc. (RXRX)'s stock forecast?
Analysts predict Recursion Pharmaceuticals, Inc. stock to fluctuate between $3.79 (low) and $12.36 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Recursion Pharmaceuticals, Inc.'s market capitalization?
As of 2025-09-12, Recursion Pharmaceuticals, Inc.'s market cap is $2,063,921,790, based on 427,313,000 outstanding shares.
How does Recursion Pharmaceuticals, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Recursion Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Recursion Pharmaceuticals, Inc. (RXRX) stock?
To buy Recursion Pharmaceuticals, Inc. (RXRX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for RXRX. Place an order (Market, Limit, etc.).
What is the best time to invest in Recursion Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Recursion Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $58,839,000 | EPS: -$1.69 | Growth: 6.96%.
Where can I find Recursion Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.recursion.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Recursion Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Recursion Pharmaceuticals, Inc. stock?
All-time high: $31.45 (2021-08-05) | All-time low: $3.79 (2025-04-09).
What are the key trends affecting Recursion Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. Mid-cap Biotech Equity Research here at the firm.
seekingalpha.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Ben Taylor - CFO & President of Recursion UK Conference Call Participants Andrew Pucher Presentation Andrew Pucher Welcome to this afternoon session with Recursion. My name is Andrew Pucher.
fool.com
It's certainly no secret that artificial intelligence (AI) has the potential to change, well, everything for most industries. It's already reshaped several sectors, in fact, and promises to reshape even more in the foreseeable future.
fool.com
According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (RXRX 3.35%) stock was shedding more than 17% of its value week-to-date as of Thursday night.
247wallst.com
Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the great GPU kingpin Nvidia (NASDAQ:NVDA).
zacks.com
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
fool.com
Before market open on Tuesday, Recursion Pharmaceuticals (RXRX -4.74%) published its latest set of quarterly earnings and business update. It might have wished it hadn't, as those quarterly numbers clearly didn't impress the market.
seekingalpha.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Ben R. Taylor - CFO & President of Recursion UK Christopher C.
zacks.com
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.4 per share a year ago.
fool.com
Recent history has, once again, demonstrated that relatively small biotech companies can see their shares soar significantly on positive developments. Summit Therapeutics' stock is up by more than 2,000% over the past three years, and Abivax, a France-based drugmaker, is up by more than 800% this year following strong clinical data.
See all news
